Table 1.
Demographic and clinical data of the patients with STEMI receiving either Genous or TAXUS Liberté stents in primary percutaneous coronary intervention (pPCI).
Table 2.
Angiographic and procedural data of patients with STEMI receiving either Genous or TAXUS Liberté stents in primary percutaneous coronary intervention (pPCI).
Fig 1.
Major adverse cardiac and cerebrovascular events (MACCE) in patients with STEMI who received Genous or TAXUS LIBERTÉ stents in primary percutaneous coronary intervention.
(A) Primary endpoint: MACCE cumulative 9-year adverse events. (B) and (C) Secondary endpoints death, repeated acute myocardial infarction (re-AMI), target vessel revascularization (TVR), and stroke in patients who received Genous or TAXUS Liberté stents in primary PCI in STEMI. *p<0.05 between the Genous and TAXUS Liberté groups.
Table 3.
List of major adverse cardiac and cerebrovascular events (MACCE, primary endpoint) during the 9-year follow-up in patients with STEMI receiving either Genous or TAXUS Liberté stents during the primary percutaneous coronary intervention (pPCI).
Cumulative MACCE rate is calculated as one event/ patient.
Fig 2.
Kaplan-Meier major adverse cardiac and cerebrovascular event- (MACCE)-free survival in patients with STEMI who received Genous or TAXUS Liberté stents in primary percutaneous coronary intervention.
(A) Cumulative MACCE-free survival. (B) Forest plot of MACCE-free survival in the indicated subgroups. CI = confidence interval; DM = diabetes mellitus; LAD = left anterior descending coronary artery; Nr = number.
Fig 3.
Kaplan-Meier survival analysis in patients with STEMI who received either Genous or TAXUS Liberté stents at the primary percutaneous coronary intervention.
(A) Cumulative survival. (B) Forest plot of survival in the indicated subgroups. CI = confidence interval; DM = diabetes mellitus; LAD = left anterior descending coronary artery; Nr = number.
Fig 4.
Kaplan-Meier analysis of target vessel revascularization (TVR)-free survival in patients with STEMI who received Genous or TAXUS Liberté stents in primary percutaneous coronary intervention.
(A) Cumulative TVR-free survival. (B) Forest plot of TVR-free survival in the indicated subgroups. CI = confidence interval; DM = diabetes mellitus; LAD = left anterior descending coronary artery; Nr = number.
Table 4.
List of procedural, in-hospital, 6-month, 1 and 9-year adverse cardiac events in patients with STEMI receiving Genous stents in primary percutaneous coronary intervention (pPCI), with or without prior statin treatment.
Each event has been counted; while cumulative MACCE rate is calculated as one event/ patient.
Table 5.
Main Genous studies.
Table 6.
Main outcomes of the Genous studies.